References:

  1. Huisman, M.V. et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014;167:329-34.

Registry Design

GLORIA™-AF is a global Registry Program run in different phases. Patient characteristics, clinical usage patterns and patient outcomes of anticoagulation therapy will be documented in up to 2200 sites and up to 50 countries throughout the world.

To reflect the real-world setting, sites participating in GLORIA™-AF will range from general practices, specialist offices, community hospitals, university hospitals to outpatient care centers and anticoagulation clinics.

GLORIA™-AF Registry Program overview
Why Are Registries Important?

Patients enrolled in the GLORIA™-AF Registry are newly diagnosed with non-valvular AF and each patient is at risk for stroke with one or more risk factors as defined by the CHA2DS2-VASc stroke risk score. Each patient's stroke risk and bleeding risk will be assessed.

Taken together the data from the GLORIA™-AF Registry Program will further the scientific knowledge on the long-term antithrombotic therapy for stroke prevention and contribute to the management of patients with atrial fibrillation in clinical practice (23).

GLORIA™-AF Registry Program overview
Gloria-AF Registry Program overview

The total number of patients enrolled in the GLORIA™-AF Registry Program could be up to 56,000 patients worldwide from up to 50 countries.